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One-Year Unadjusted and Adjusted Hazard Ratios for Adverse Events in
Patients Stratiﬁed by Smoking Status
Smokers
(n¼9,299)
Non-
smokers
(n¼21,570)
Unadjusted
HR [95% CI] p-value
Adjusted
HR
[95% CI] p-value
Death 222 (2.6) 621 (3.3) 0.83
[0.72,0.97]
0.02 1.71
[1.44,
2.04]
<0.0001
Cardiac death 133 (1.5) 378 (2.0) 0.82
[0.67,1.00]
0.05 1.55
[1.24,
1.95]
0.0001
Myocardial
reinfarction
492 (5.5) 1077 (5.2) 1.06
[0.96,1.18]
0.25 1.19
[1.06,
1.35]
0.005
Target vessel
revascularization
622 (7.3) 1517 (7.4) 0.96
[0.88,1.06]
0.41 0.93
[0.84,
1.03]
0.16
Deﬁnite/
probable stent
169 (1.9) 193 (1.0) 2.05
[1.67,2.52]
<0.0001 2.05
[1.65,
<0.0001
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Background: Percutaneous coronary intervention (PCI) of calciﬁed lesions has been
shown tobeassociatedwithworse ischemicoutcomes in several studies. These studieswere
limited by a high rate of bare-metal stents and drug-eluting stents (DES) of ﬁrst generation
use, and infrequent usage of intra-vascular ultrasound (IVUS) for PCI optimization. We
sought to determine the frequency and impact of coronary calciﬁcation (CCA) among
patientsundergoingPCI in the contemporarydrug-eluting stent erawith frequent IVUSuse.
Methods: ADAPT-DES was a prospective, multicenter registry of patients success-
fully treated with one or more drug-eluting stents. Patients were stratiﬁed and 1-year
outcomes compared according to the presence of CCA (per site operator assessment)
of the target lesion.
Results: Among8,578patientswhounderwent PCI inADAPT-DES,CCAwaspresent in
2646/8578 (30.8%) patients. IVUSwas used in 3349 (39.0%) patients of the entire cohort.
CCAwas more frequent in advanced age, hyperlipidaemia, hypertension, history of renal
insufﬁciency, presence of multi-vessel disease, low white blood cell count, and IVUS
guided-PCI. The unadjusted 1-year rate of death, myocardial infarction (MI), ischemic
target vessel revascularization (TVR), and major adverse cardiac events (MACE) were
signiﬁcantly increased in patients with presence of CCA (Table). By multivariable anal-
ysis, also adjusting for IVUS use, the presence of CCA was an independent predictor of
1-year ischemia-driven TVR (HR [95%CI] 1.20 [1.00, 1.45], p¼0.05), myocardial
infarction (HR 1.77 [1.37, 2.27], p< 0.0001), death-MI (HR 1.66 [1.35, 2.04], p< 0.0001)
and MACE (HR¼1.41 [1.19, 1.68] p< 0.0001). No signiﬁcant interaction was detected
between the presence of CCA, IVUS use, and all ischemic outcomes.
Conclusions: CCA was associated with worse outcomes after DES PCI despite high
rate of IVUS usage.Table. One-year Outcomes According to the Presence of Coronary
Calciﬁcation
Calciﬁed lesions
(N¼2646)
Non-calciﬁed Lesions
(N¼5932)
P-value
Death 2.6% (69) 1.6% (92) 0.002
Cardiovascular 1.5% (40) 1.1% (60) 0.06
Death/MI 7.0% (184) 3.8% (220) <0.0001
Myocardial infarction 4.7% (124) 2.5% (145) <0.0001
Ischemia-driven TVR 7.2% (191) 5.5% (325) 0.002
ST deﬁnite/probable 0.9% (24) 0.8% (46) 0.58
Major adverse
cardiac events
8.9% (233) 5.9% (337) <0.0001
Major adverse cardiac events is a composite of cardiac death, myocardial infarction or target
lesion revascularization; TVR¼target vessel revascularization; ST¼stent thrombosis
thrombosis 2.54]
Major adverse
cardiac events
1116 (12.8) 2762 (13.5) 0.94
[0.88,1.01]
0.10 1.06
[0.97,
1.15]
0.19
Data presented as n (%); Major adverse cardiac events include death, reinfarction and target
vessel revascularization.
Variables included in multivariable analysis: age, male, diabetes, hyperlipidemia, hyperten-
sion, prior myocardial infarction, prior PCI, prior coronary artery bypass graft surgery, number
of stents, number of vessels treated, and smokingTCT-110
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Background: Available data on relationship between smoking status and outcomes
among patients (pts) undergoing percutaneous coronary intervention (PCI) are con-
ﬂicting. We sought to further clarify this relationship.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AngioplasMethods: Patient-level pooled data from 18 prospective randomized trials (RAVEL,
E-SIRIUS, SIRIUS, C-SIRIUS, TAXUS I-II, TAXUS IV-VI, ENDEAVOR II-IV,
SPIRIT II-IV, ACUITY, HORIZONS-AMI and COMPARE) were pooled. Pts were
stratiﬁed by their current smoking status prior to randomization. One-year ischemic
outcomes were compared between the 2 groups.
Results: Among the 30,869-pooled pts, 9,299 (30.1%) were actively smoking before
PCI. At baseline, smokers were younger, less likely to have diabetes, dyslipidaemia,
prior MI, PCI or CABG. Angiographically, they had less complex (severe calciﬁca-
tions or tortuosity) and less extensive CAD at baseline. At 1 year, smokers had lower
unadjusted rates of death and cardiac death. However, after adjustment for potential
cofounders, smoking status at baseline was identiﬁed as a strong independent pre-
dictor of all ischemic endpoints at 1 year, including death, cardiac death, and stent
thrombosis (Table).
Conclusions: Results from this large pooled analysis of pts undergoing PCI
demonstrated that the “smoker’s paradox” represents a statistical artefact, most
likely related to the lack of adjustment for potential cofounders. Smoking remains
an important predictor of poor outcomes after PCI and should be strongly
discouraged.TCT-111
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Background: HIV is associated with premature coronary artery disease (CAD) and
increased risk of adverse events. It has been shown that women have higher morbidity
than men in this setting, perhaps due to the young age of this population. However,
little is known about the sex-based differences angiographic pattern or burden of CAD
in this population.
Methods: We followed 93 consecutive patients with HIV who underwent PCI from
2003 to 2011 at our center. Quantitative coronary angiographic (QCA) analysis wasty Overview and Outcomes B33
